Second Sight touts 3-year Argus II retinal prosthesis data

Second Sight Medical (NSDQ:EYES) said data from a 3-year study of its Argus II retinal prosthesis system show positive results in previously blind patients. The study, published in Ophthalmology yesterday, examined 30 patients implanted with the Argus II, designed to restore partial vision by stimulating viable retinal cells in patients with severe to profound retinitis pigmentosa, the Sylmar, Calif.-based company said. At 3 years, 29 patients remain implanted with the system and 89% of subjects performed better with the system in visual function tasks, the study reports. Eighty percent of patients benefited from the system according to a functional low-vision observer rated assessment of patients with the device, the study reports, and no subjects were affected negatively. “We are thrilled to see positive results from this study, supporting the safety and benefit of the Argus II. The results from the trial demonstrated long-term reliability of the device, long-term benefit to the users, and an acceptable safety profile. Together, these results show that the Argus II provides a substantial visual improvement over blindness. Having this device backed by significant, long-term clinical data is cause for great hope among those individuals suffering from RP and should further our efforts across the globe in securing regulatory and reimbursement approvals,” CEO Dr. Robert Greenberg said in a press release. At 1 year, 66% of subjects had no device or surgical serious ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Implants Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news